1064-nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma
Launched by TAIPEI MEDICAL UNIVERSITY WANFANG HOSPITAL · Dec 29, 2016
Trial Information
Current as of April 29, 2025
Unknown status
Keywords
ClinConnect Summary
METHODS: Twenty patients with melasma were included in a randomized controlled observer-blinded study with split-face design. Each side of the face was randomly allocated to either six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz) or low influence 1064nm Nd:YAG laser combined with intradermal tranexamic acid injection.Complication Improvement of melasma was assessed by Melasma area severity index (MASI),physician's global assessment (PhGA), MELASQOL scale, patient's global assessment (PGA), and patient's satisfacti...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients \> 20 years old with refractory melasma to topical treatment
- Exclusion Criteria:
- • History of keloid, active eczema, active acne in the face, history of facial eczema, photosensitivity, use of isotretinoin in the past 6 months, pregnancy, and high exposure to sunlight or UV light (UVA or UVB)
About Taipei Medical University Wanfang Hospital
Taipei Medical University Wan Fang Hospital is a leading healthcare institution in Taiwan, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital combines cutting-edge medical technology with a multidisciplinary approach to research, facilitating innovative studies that address critical health challenges. With a focus on ethical standards and patient safety, Wan Fang Hospital collaborates with a network of medical professionals and researchers to contribute valuable insights to the global medical community. Its dedication to excellence in clinical trials underscores its role as a pivotal player in the advancement of healthcare practices and therapeutic developments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yu Chen Huang, MD
Principal Investigator
Taipei Medical University WanFang Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials